Hanmi Pharm한미약품
128940 · KOSPI · ₩128940 · 한미약품
Analyst target price
Average target
₩666,667
Upside
+80.4%
Range ₩600,000 – ₩700,000 · 3 brokers (latest target within 6 months)
Buy 3
Consensus target vs price, 2 years
Earnings estimates
Brokers' earnings estimates and how they've been revised, with Pro.
Unlock with ProBroker reports
| Date | Broker | Report | Rating | Target | Change | Upside | Since publish | Read |
|---|---|---|---|---|---|---|---|---|
| Oct 28 | Kyobo Securities | 3Q26 Review: Beijing Hanmi Recovery Needed | Buy | ₩600,000 | Maintained | +62.4% | 0.0% | Read ↗ |
| Oct 28 | Mirae Asset Securities | Hanmi Pharm (128940/Buy): Passing the Peak of Concerns | Buy | ₩700,000 | New | +89.4% | 0.0% | Read ↗ |
| Oct 28 | Kyobo Securities | 3Q26 Review: Beijing Hanmi Recovery Needed | Buy | ₩600,000 | Cut | +62.4% | 0.0% | Read ↗ |
All 11 broker reports on Hanmi Pharm, not just the latest 3, with Pro.
Unlock with ProCalculated by JONBUR from publicly available broker reports. Reports belong to their publishers. Not financial advice. Includes brokers that publish research publicly; some brokers' reports are client-only and not included.
Reported in the news
| Date | Broker | Target | Change | Rating | Source |
|---|---|---|---|---|---|
| Oct 20 | iM Securities | — | Cut | — | Reported by Money Today |
| Oct 14 | — | ₩710,000(₩730,000) | Cut | — | Reported by The Financial News |
| Oct 14 | — | ₩710,000 | Cut | — | Reported by Money Today |
| Oct 13 | Kiwoom Securities | — | Cut | — | Reported by The Korea Economic Daily |
Target prices and ratings as news headlines report them, for every broker, including the ones whose reports we don't collect. Only what the headline says; open the article for the rest. Not financial advice.
AI summary of public information
An AI summary of the public information on this company: filed financial statements, filings, prices and news headlines. It doesn't use broker reports; their targets and estimates are shown above.
Hanmi Pharm's cumulative revenue passed ₩1.2T in Q3 2026, but profit fell sharply in the quarter and the share price is down over the past month.
Hanmi Pharm is a Korean drugmaker with a trailing twelve-month revenue of ₩1.66T and net income of ₩217B as of H1 2026. Preliminary Q3 2026 results show revenue of ₩377.4B, up 4.2% year on year, while operating profit of ₩37.8B fell 31.3% and net profit dropped 69.1%, which news reports tie to weak performance at Beijing Hanmi. The shares closed at ₩352,500 on 2026-10-26, down 32.2% over one month but up 4% over one year.
What stands out
- Q3 2026 revenue rose 4.2% year on year to ₩377.4B, but operating profit of ₩37.8B fell 31.3%, according to news reports on the preliminary results.
- Cumulative revenue for the first three quarters was about ₩1.2T, which news reports describe as the first time in three quarters the figure passed that level.
- Trailing operating margin is 19.5% and net margin is 13.1%, both higher than the 2025 full-year levels of 16.7% and 11.0%.
- The fair value model's base case is ₩258,849 per share, below the current price of ₩352,500; the bear case is ₩167,604 and the bull case is ₩411,213.
- Recent filings include a share cancellation decision and preliminary earnings, and news reports name Beijing Hanmi's weak performance as a drag.
What to watch
- The full Q3 earnings release and how the Beijing Hanmi segment performs in coming quarters, as the data flags it as a continuing risk.
- The share cancellation decision and its effect on share count and capital, which the filings do not detail in the data provided.
- Institutional selling of about ₩27.7B over the last 20 trading days, while foreign ownership fell from 14.4% to 12.9%.
Data as of Oct 26, 2026 · written 2d ago
This is not financial advice.
Also known as: Hanmi Pharm / 한미약품 / 128940 / KRX:128940
Source: KRX statistical information